Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Genzyme Calls Sanofi OfferInadequate

by Rick Mullin
November 1, 2010 | A version of this story appeared in Volume 88, Issue 44

At a recent analysts’ meeting in New York City, Genzyme executives outlined why they believe an $18.5 billion takeover bid by Sanofi-Aventis “dramatically undervalues” their company. They said they expect 2011 earnings will be more than double 2010 earnings and 20% higher than analysts’ estimates. Genzyme highlighted the blockbuster potential of alemtuzumab, its developmental drug for multiple sclerosis. Genzyme says Sanofi’s bid of $69.00 per share is 20 times analysts’ 2011 earnings-per-share consensus estimates. If the same multiple were applied to Genzyme’s expectations, it says, the offer would be $89.00 per share.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.